Unconfigured Ad

Collapse

Onso from Pacific Biosciences: Latest Sequencing Technologies—Part 4

Collapse
X
Collapse
  •  

  • Onso from Pacific Biosciences: Latest Sequencing Technologies—Part 4

    Onso was the second sequencer Pacific Biosciences (PacBio) revealed during this year’s American Society of Human Genetics meeting (read about the first sequencer here). This benchtop sequencer uses sequencing by binding (SBB), a method unlike any other instrument on the market. SBB incorporates native nucleotides, has reduced molecular scarring, and reportedly results in significantly higher accuracy base calls than traditional short-read sequencers. The following sections highlight the important specifications of this unique device.
    Click image for larger version  Name:	img_onso_left_closed-Copy.png Views:	0 Size:	127.7 KB ID:	323427
    Image of Onso (courtesy of PacBio)


    Read type and length
    Onso is PacBio’s first and only short-read sequencer. This new instrument has two available reagent kits (200- and 300-cycle). The read lengths can be configured at 2 x 100 bp or 1 x 200 bp with a 200-cycle kit, or 2 x 150 bp with a 300-cycle kit. Both options have high quality scores of ≥90% Q40+.

    Flow cell/SMRT Cell options
    Instead of a SMRT Cell, like other PacBio sequencers, Onso operates on a single, dual-lane flow cell. Prior to initiating the sequencing run, each lane can be loaded with separate pools of single or multiplexed samples.

    Data output
    The data output is 80–100 Gb using a 200-cycle kit with an expected run time of 32 hours, while the 300-cycle kit has a data output of 120–150 Gb with a 48-hour run time. The number of expected reads for each sequencing run is 400–500 M.

    Analysis options
    FASTQ generation can be completed on the instrument and demultiplexing is also expected to be offered onboard during the final release. The resulting data can then be easily combined with many existing tools for secondary analysis.

    Common applications
    • Cancer screening (cfDNA) and research
    • Single-cell sequencing
    • Whole exome sequencing
    • Biomarker discovery

    Release date
    Those interested in Onso can place orders with PacBio and shipments are anticipated for the first half of 2023.

    Highlights
    • The first short-read sequencer from PacBio and a compact benchtop instrument.
    • Uses sequencing by binding, a unique short-read method with an increased sensitivity that lowers the limit of detection.
    • Collaborations with 10x Genomics, Twist Biosciences, and other well-known vendors to streamline protocols onto the new device.
    • Ultra-high Q40+ data quality allows for a decrease in read depth needed for accurate analysis.
    • Low duplication rates, minimal index-hopping, and the ability to fully resolve low-complexity regions better than SBS technology.

    To compare sequencing technologies please visit Biocompare
      Please sign into your account to post comments.

    About the Author

    Collapse

    seqadmin Benjamin Atha holds a B.A. in biology from Hood College and an M.S. in biological sciences from Towson University. With over 9 years of hands-on laboratory experience, he's well-versed in next-generation sequencing systems. Ben is currently the editor for SEQanswers. Find out more about seqadmin

    Latest Articles

    Collapse

    • How Immunogenomics Decodes Immunity’s Genetic Blueprint
      by SEQadmin2




      The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.

      This convergence of genetics, immunology, and computation...
      Today, 05:41 AM
    • Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Working...